| Popis: |
Background: Cancer patients are more susceptible to infections and potentially at higher risk to develop COVID-19 Tumor type and antitumor treatment may also affect both the susceptibility to and the severity of SARS COV-2 Methods: To analyze the distribution of patients who developed COVID-19 during active antineoplastic therapy and the related clinical course by tumor type, stage and class of oncologic treatment (chemo, immune, biologic, other) a multicenter, retro-prospective, observational study was proposed to the Hospital Medical Oncologic Units of the National Health Service in Italy (168 centers of the Collegio Italiano dei Primari Oncologi Medici Ospedalieri -CIPOMO) Data were collected on demographics, tumor characteristics, treatment setting, type of ongoing anti-cancer therapy and COVID-19 clinical course (phenotype, hospitalization, therapy, duration and outcome) Eligibility required a positive COVID-19 molecular test before May 4th, 2020 and at least 1 course of antitumor therapy delivered after January 15th Results: At the present analysis data are available for 116 of 168 centers (7 declined, 28 pending, 17 data awaited) 64 of 116 centers (55%) had COVID-19 positive cases (cases /center: median 3, range 1-40) At these 64 centers, 283 positive cases (males 158, 55 9% - females 125, 44 1%;median age 67 years, range 28-89) were observed among a total population of 40894 patients receiving active treatment between January 15 and May 4 2020 65 of 283 (23%) had cardiovascular comorbidities and 7 (2%) pre-existent pulmonary disease 239/283 patients (84 4%) were receiving treatment for metastatic disease and 44 (15 6%) in the adjuvant setting Breast, lung, colon and prostate cancer were the main tumor types accounting for 61 % of cases Conclusions: The occurrence of COVID-19 among cancer patients receiving active antitumor treatment appears to reflect tumor epidemiology Full analysis of the distribution of COVID-19 occurrence and clinical course by tumor type, stage and oncologic treatment will be presented Legal entity responsible for the study: The authors Funding: Has not received any funding Disclosure: All authors have declared no conflicts of interest |
